Articles from Synedgen, Inc.

Synedgen, Inc., a biotechnology company with a validated platform targeting human glycobiology to treat a range of diseases including gastrointestinal targets, today announced that it has promoted Dr. Laura Saward, PhD, to be the company’s President and Chief Executive Officer. Dr. Saward joined Synedgen in 2024 in the capacity of Chief Scientific Officer to launch their transformative program for GI Acute Radiation Syndrome, and she will continue to serve in this role as well.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced the publication of preclinical data that shows MIIST305 mitigating gastrointestinal acute radiation syndrome (GI-ARS) injury and ameliorating radiation-induced gut microbiome dysbiosis in a murine model. The paper has been published in Gut Microbes and is coauthored by Synedgen and its research collaborators at Columbia University’s Center for Radiological Research. You can read the full article here.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced the appointment of Dr. Laura Saward, PhD, as the company’s Chief Scientific Officer.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced that it has been awarded a $2.2 million contract from the Joint Warfighter Medical Research Program (JWMRP) for the development of its lead therapeutic, MIIST305, as a prophylactic radiation countermeasure.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced a partnership valued at up to $119 million over a six-year period with the Biomedical Advanced Research and Development Authority (BARDA), a center within the Administration for Strategic Preparedness and Response, part of the U.S. Department of Health and Human Services. This contract aims to develop Synedgen’s lead therapeutic, MIIST305, to address Gastrointestinal Acute Radiation Syndrome (GI-ARS) arising from acute exposure to ionizing radiation. The initial phase of the award provides up to $17 million for proof-of-concept studies in two animal models. If all options are exercised, this BARDA contract will advance MIIST305 development through U.S. Food and Drug Administration (FDA) approval and contribute to the field of medical countermeasures research by optimizing a new nonclinical GI-ARS model for FDA acceptance.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced the appointment of Dr. Hal J. Oien to its board of directors.

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced it has completed IND-enabling studies for its lead candidate, MIIST305. MIIST305 is being developed for two parallel programs, an indication for ulcerative colitis (UC) and a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). Within a year, Synedgen plans to open an Investigational New Drug (IND) application for MIIST305 and initiate a Phase 1 clinical study to support both programs. Derived from Synedgen’s Multivalent Immune Signaling Target (MIIST) platform, MIIST305 is an orally delivered, gut-restricted, tissue regenerative drug candidate.